Kim HJ - Search Results

1

Imatinib Mesylate Dose Adjustment Based on Body Surface Area for CML Chronic Phase Patients Intolerant to Standard Dosage.

Sung HJ, Lee SR, Choi IK, Park Y, Choi CW, Kim HJ, Yhim HY, Kim BS. Sung HJ, et al. Among authors: kim bs, kim hj. Acta Haematol. 2015;134(1):59-68. doi: 10.1159/000369444. Epub 2015 Apr 11. Acta Haematol. 2015. PMID: 25871321

2

Retrospective multicenter study of allogeneic peripheral blood stem cell transplantation followed by reduced-intensity conditioning or conventional myeloablative regimen.

Kim DH, Sohn SK, Baek JH, Kim JG, Lee JW, Min WS, Kim DW, Choi SJ, Lee JH, Lee KH, Lee MH, Lee JJ, Kim HJ, Kim CC, Lee KB. Kim DH, et al. Among authors: kim cc, kim hj, kim dw, kim jg. Acta Haematol. 2005;113(4):220-7. doi: 10.1159/000084674. Acta Haematol. 2005. PMID: 15983427

3

Pilot remission induction therapy with idarubicin, plus an intensified dose of ara-C and priming with granulocyte colony-stimulating factor for acute myeloid leukemia.

Baek JH, Sohn SK, Kim DH, Kim JG, Yang DH, Kim YK, Lee JJ, Kim HJ. Baek JH, et al. Among authors: kim yk, kim hj, kim dh, kim jg. Acta Haematol. 2007;117(2):109-14. doi: 10.1159/000097386. Epub 2006 Nov 28. Acta Haematol. 2007. PMID: 17135724 Clinical Trial.

4

Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia.

Kim DH, Kamel-Reid S, Chang H, Sutherland R, Jung CW, Kim HJ, Lee JJ, Lipton JH. Kim DH, et al. Among authors: kim hj. Haematologica. 2009 Jan;94(1):135-9. doi: 10.3324/haematol.13151. Epub 2008 Dec 9. Haematologica. 2009. PMID: 19066329 Free PMC article.

5

Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy.

Goh HG, Kim YJ, Kim DW, Kim HJ, Kim SH, Jang SE, Lee J, Kim D, Kim WS, Park SH, Kweon IY. Goh HG, et al. Among authors: kim yj, kim hj, kim dw, kim sh, kim d, kim ws. Leuk Lymphoma. 2009 Jun;50(6):944-51. doi: 10.1080/10428190902926973. Leuk Lymphoma. 2009. PMID: 19479613

6

The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia.

Lee SR, Yang DH, Ahn JS, Kim YK, Lee JJ, Choi YJ, Shin HJ, Chung JS, Cho YY, Chae YS, Kim JG, Sohn SK, Kim HJ. Lee SR, et al. Among authors: kim yk, kim hj, kim jg. J Korean Med Sci. 2009 Jun;24(3):498-503. doi: 10.3346/jkms.2009.24.3.498. Epub 2009 Jun 15. J Korean Med Sci. 2009. PMID: 19543516 Free PMC article.

7

Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.

Koh Y, Kim I, Yoon SS, Kim BK, Kim DY, Lee JH, Lee KH, Park E, Kim HJ, Sohn SK, Joo YD, Kim SJ, Chung J, Shin HJ, Kim SH, Kim CS, Song HS, Kim MK, Hyun MS, Ahn JS, Jung CW, Park S; Korean Society of Hematology CML working party. Koh Y, et al. Among authors: kim cs, kim hj, kim dy, kim sh, kim sj, kim bk, kim i, kim mk. Ann Hematol. 2010 Jul;89(7):725-31. doi: 10.1007/s00277-010-0910-8. Epub 2010 Feb 24. Ann Hematol. 2010. PMID: 20179930 Clinical Trial.

8

Coexisting with clonal evolution and BCR-ABL mutant in CML patients treated with second-generation tyrosine kinase inhibitors predict the discrepancy of in vitro drug sensitivity.

Ahn JS, Kim YK, Lee SR, Yu L, Yang DH, Cho SH, Shim HJ, Bae WK, Lee JJ, Chung IJ, Shin MG, Kim HJ. Ahn JS, et al. Among authors: kim yk, kim hj. Cancer Res Treat. 2010 Mar;42(1):37-41. doi: 10.4143/crt.2010.42.1.37. Epub 2010 Mar 31. Cancer Res Treat. 2010. PMID: 20369050 Free PMC article.

9

Change in serum proteome during allogeneic hematopoietic stem cell transplantation and clinical significance of serum C-reactive protein and haptoglobin.

Ryu J, Lee SR, Park SG, Kang S, Kim HJ, Park BC. Ryu J, et al. Among authors: kim hj. Exp Mol Med. 2010 Sep 30;42(9):651-61. doi: 10.3858/emm.2010.42.9.065. Exp Mol Med. 2010. PMID: 20716902 Free PMC article.

10

The IFNG (IFN-gamma) genotype predicts cytogenetic and molecular response to imatinib therapy in chronic myeloid leukemia.

Kim DH, Kong JH, Byeun JY, Jung CW, Xu W, Liu X, Kamel-Reid S, Kim YK, Kim HJ, Lipton JH. Kim DH, et al. Among authors: kim yk, kim hj. Clin Cancer Res. 2010 Nov 1;16(21):5339-50. doi: 10.1158/1078-0432.CCR-10-1638. Epub 2010 Oct 19. Clin Cancer Res. 2010. PMID: 20959405

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

21,015 results

Search Page